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Open access under CC BY-NS-nitrosoglutathione (GSNO) at low concentration inhibits platelet aggregation without causing vasodi-
lation, suggesting platelet-selective nitric oxide delivery. The mechanism of this selectivity is unknown,
but may involve cell surface thiol isomerases, in particular protein disulphide isomerase (csPDI)
(EC 5.3.4.1). We have now compared csPDI expression and activity on platelets, endothelial cells and vas-
cular smooth muscle cells, and the dependence on thiol reductase activity of these cell types for NO
uptake from GSNO.
csPDI expression was measured by ﬂow cytometry and its reductase activity using the pseudosubstrate
dieosin glutathione disulphide. This activity assay was adapted and validated for 96-well plate format.
Flow cytometry revealed csPDI on all three cell types, but percentage positivity of expression was higher
on platelets than on vascular cells. Consistent with this, thiol isomerase-related reductase activity was
higher on platelets (P < 0.01), and cellular activation (with either phorbol myristate acetate or ionomycin)
increased csPDI activity on both platelets and smooth muscle cells, but not on endothelium. Intracellular
NO delivery from GSNO was greater in platelets than in vascular cells (P < 0.002), and was more sensitive
to thiol isomerase inhibition using phenylarsine oxide (P < 0.05).
Increased surface thiol isomerase activity on platelets, compared with cells of the vascular wall, may
explain the platelet-selective actions of GSNO and help deﬁne its antithrombotic potential.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Thiol isomerases comprise the thioredoxin superfamily of oxido-
reductases, characterised by the presence of one or more thiore-
doxin-like domains containing the CXXC motif [1].
Over the last decade thiol isomerases located at the cell surface,
most prominently protein disulphide isomerase (EC 5.3.4.1), have
emerged as regulators of platelet function [2–6], and of tissue
factor activity [7–9]. Cell surface protein disulphide isomerase
(csPDI) inﬂuences both ﬁbrin generation and platelet thrombus
formation in mouse models (8), conﬁrming that csPDI is relevant
to in vivo haemostatic regulation.
A further cellular action of csPDI relevant to haemostasis and
vascular regulation is to facilitate delivery across the plasma mem-
brane of nitric oxide (NO) signalling [10,11]. Our own previous
studies have shown that csPDI is required for the delivery into
platelets of a range of NO redox derivatives [12] and that during thisence, University of Westmin-
UK. Fax: +44 207911 5087.
dge).
5th Floor Tower Wing, Guys
C-ND license.process csPDI undergoes thiol modiﬁcation [13]. NO supplementa-
tion by means of donor drugs is a potentially useful antithrombotic
strategy in patients suffering from cardiovascular disease due to
endothelial dysfunction [14], and the anti-thrombotic action of S-
nitrosothiols (RSNOs) has attracted particular interest because cer-
tain of these compounds show evidence of platelet-selective action
[15]. For example, administration of low doses of S-nitrosoglutathi-
one (GSNO) to human patients produced platelet inhibitionwithout
signiﬁcant vasodilation [16]. This suggests preferential NO signal-
ling into platelets, perhaps via differences in GSNO metabolism
between platelets and cells of the blood vessel wall. Because of
the role of csPDI in NO delivery, it is important to establish whether
there are differences in the expression or activity of this enzyme
between platelets and vascular cells.
PDI displays both oxidase and reductase, as well as thiol isomer-
ase activity [1], however since themechanism of its S-denitrosation
of GSNO involves electron donation by the active site thiols [17],
measurement of its reductase activity is most relevant in this con-
text. A novel ﬂuorescent assay sufﬁciently sensitive to measure
reductase activity of cell surface thiol isomerases has recently been
published [18] and we have therefore used this technique, adapted
in 96-well plate format, to compare thiol reductase on platelets,
endothelial cells and vascular smooth muscle cells. Our aim was
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ity between the cell types and to determine whether preferential
NO delivery into platelets might be explained on this basis.Materials and methods
Chemicals
DAF-FM (4-amino-5-methylamino-2070 diﬂuoroﬂuorescein)
diacetate was obtained from Molecular Probes (Paisley, UK). GSNO
(S-nitroso-l-glutathione) was obtained from Alexis Biochemicals
(Exeter, UK). Mouse anti-PDI antibody (1D3) conjugated R-
Rhycoerythrin (PE) and PE-labeled isotype-matched control anti-
body (mouse IgG1) were obtained from Assay Designs (Exeter,
UK). Live/Dead Fixable Dead Cell Stain Kits was obtained from Invit-
rogen (Paisley,UK). BCAprotein assaykitwasobtained fromThermo
Scientiﬁc (Northumberland, UK). PD-10Desalting columnswere ob-
tained fromGEHealthcare (Buckinghamshire, UK). Dulbecco0s Phos-
phate Buffered Saline (D-PBS) and Fetal bovine serum (FBS) were
obtained fromLonzaWorkinghamLtd. (Slough, UK). All other chem-
icals were purchased from Sigma (Poole, UK).
Preparation of dieosin glutathione disulphide (Di-E-GSSG)
The synthetic pseudosubstrate dieosin glutathione disulphide
(Di-E-GSSG) was generated by incubation of GSSG (100 lM) with
a 10-fold molar excess of eosin isothiocyanate (1 mM) in phos-
phate buffer (100 mM potassium phosphate and 2 mM EDTA, pH
8.8) overnight at room temperature as previously described [18]
with minor modiﬁcation. One hundred microliters aliquots were
taken and passed down a PD-10 desalting column (Sephadex G-
25) using 0.1 M potassium phosphate buffer, pH 7.0, containing
2 mM EDTA, and 1 ml aliquots were collected. The eluted fractions
were tested for ﬂuorescence increase before and after the addition
of DTT (10 mM) by monitoring at 545 nm with excitation at
525 nm. All fractions showing at least 10-fold increase in ﬂuores-
cence were pooled and stored at 20 C.
Preparation of washed platelets
Washed platelets were prepared as previously described [12].
Brieﬂy, whole blood (20 ml) was obtained with informed consent,
according to the Declaration of Helsinki, from healthy volunteers
and drawn into a 25 ml container containing 3 ml of acid citrate
dextrose. Platelet-rich plasma (PRP) was separated from other cel-
lular components of blood by centrifugation twice at 170g for
10 min, keeping the upper layer each time. PRP was acidiﬁed with
0.5 M citric acid to pH 6.2–6.5, and prostaglandin E1 (1.5 lM) and
apyrase (2 units/ml) were added to prevent aggregation during
subsequent centrifugation at 1000g for 12 min. The platelet pellet
was then resuspended in 1 ml HEPES-buffered saline (HBS) con-
taining 140 mM NaCl, 2.7 mM KCl, 5 mM glucose and 10 mM
HEPES (pH 7.3) and loaded onto a Sepharose 2B column
(1.45  5.0 cm). The platelet fraction was eluted with HBS and
the platelet count was adjusted to 108/ml before use.
Cell culture
Human coronary artery endothelial cells (HCAEC), human coro-
nary artery smooth muscle cells (HCASMC), and their culture medi-
ums were purchased from PromoCell (Heidelberg, Germany), and
cultured according to manufacturer0s instructions. Cells were pas-
saged using a solution of 0.125% trypsin and 0.02% EDTA in
Dulbecco0s PBS (D-PBS). Experiments were performed after 3–5
passages, and the cell count adjusted to 105/ml before use.Assay of PDI reductase activity
Reductase activity of cell surface thiol isomeraseswasmonitored
in a 96-well microplate ﬂuorescence assay. PDI from bovine liver
(Sigma) (10–100 nM) was incubated with Di-E-GSSG (150 nM) in
HBS containing 5 lMDTT (PDI assay buffer). The increase in ﬂuores-
cence was monitored at excitation and emission wavelengths (Ex
510 nm/Em550 nm)whichwere optimised for themicroplate read-
er (Gemini EM, Molecular Devices, Wokingham UK). The same pro-
tocol was used to monitor reductase activity of thiol isomerases on
variable numbers of platelets (1–16  107 per well). In further
experiments, platelets (2  107/well) were incubated with the thiol
isomerase inhibitor phenylarsine oxide (PAO) (12.5–100 lM) at
37 C for 30 min before addition of Di-E-GSSG (150 nM). To compare
the thiol reductaseactivity in thedifferent cells, cellular total protein
was measured in parallel using BCA kit according to the manufac-
turer0s protocol, and results normalized to the amount of cell pro-
tein. To determine the effect of cell activation, the three cell types
were incubatedwith phorbolmyristate acetate or ionomycin at con-
centrations of 1–100 lM, and cell surface thiol reductase activity
was then monitored over 45 min, as described above.Flow cytometry analysis
Cultured cells were collected by trypsinization and washed
twice in cold D-PBS by centrifugation at 150g for 6 min. The density
of washed cells and isolated platelets was then adjusted to 2  107/
mlwith D-PBS. 100 ll of the adjusted cells were incubatedwith 1 ll
of near-IR ﬂuorescent reactive dye provided with Live/Dead Fixable
Dead Cell Stain Kits for 30 min to distinguish the live and dead cells.
The dye-loaded HCAEC and HCASMC were then washed twice with
D-PBS by centrifugation at 150g for 6 min and the dye-loaded plate-
lets were ﬁnally washed in D-PBS containing 5 mM EDTA by centri-
fugation at 1000g for 6 min. Cells were then resuspended in D-PBS
containing 2% FBS and incubated with PE-PDI antibody (1:50 dilu-
tion) on ice for 30 min. PE-labeled isotype-matched control anti-
body (mouse IgG1) was used in parallel to set the ﬂuorescence
threshold for primary antibody. The expression of csPDI on the cells
was analyzed in a CyAn ADP Analyzer (DakoCytomation, Denmark).
Forward (FSC) and side scatter (SSC) were set at logarithmic gain
and triggering was set at FSC. Live cells were gated and analyzed.
In separate experiments, platelets were subjected to the tryp-
sinisation protocol described above for detachment of vascular
cells, and the effect of this on csPDI expression was assessed to
see whether expression might be affected by differences in cell
preparation procedure.Measurement of the entry of NOx (reactive nitrogen species) into cells
DAF-FM diacetate, a membrane-permeant ﬂuorescent probe,
was used for detecting intracellular NOx as previously described
[12]. Cells were suspended in HBS and then incubated with
DAF-FM diacetate (5 lM) at 37 C for 30 min. The DAF-FM-loaded
platelets were then separated from free probe on a Sepharose 2B
column. Excess DAF-FM was separated from HCAEC and HCASMC
by centrifugation. S-Nitroso-l-glutathione (GSNO) at concentra-
tions of 107–103 M was then added to the cells (105/mL) in
PDI assay buffer. Fluorescence intensity at 515 nm with excitation
at 480 nm was measured over 30 min using the microplate reader.
To take account of higher ﬂuorescence in the larger cells, data for
each cell type were expressed as a percentage of the maximum va-
lue, obtained using 1 mM GSNO. In experiments to determine the
role of thiol isomerases in NO delivery, cells were pre-incubated
with 100 lM phenylarsine oxide (PAO), a thiol isomerase inhibitor,
at 37 C for 30 min before addition of 1 mM GSNO.
Fig. 2. Inhibition of platelet surface thiol reductase activity by PAO. Washed
platelets were pre-incubated with PAO (12.5–100 lM) at 37 C for 30 min before
addition of Di-E-GSSG (150 nM) and measurement of rate of change of ﬂuorescence
(Ex 510 nm/Em 550 nm). Values are expressed as percentage inhibition vs control,
and data represent mean ± SEM from three separate experiments, each performed
in triplicate.
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All data are expressed as mean ± SEM. One-way ANOVA was
used for difference between data groups and dose response curves
were compared using two-way ANOVA followed with Bonferroni
post hoc correction for multiple comparisons. Differences were
considered signiﬁcant when P < 0.05.
Results
Reductase activity of bovine liver PDI and platelet cell surface thiol
isomerases
The ﬂuorescent thiol reductase assay employing Di-E-GSSG,
ﬁrst described by Raturi and Mutus [18] was successfully adapted
for use in 96-well microplate format, as shown by reproducible and
dose dependent activity of bovine liver PDI (Fig. 1A) and of cell sur-
face thiol isomerases on platelets (Fig. 1B), which was inhibited in
a dose dependent manner by the thiol isomerase inhibitor PAO
(Fig. 2).
Comparison of csPDI expression and thiol isomerase activity on
platelets, endothelial cells and vascular smooth muscle cells
csPDI was detected by ﬂow cytometry on platelets, HCAEC and
HCASMC (Fig. 3A). Both endothelial and smooth muscle cells
showed more variable expression than platelets (Fig. 3B) and when
compared in terms of percentage positive cells, the level of the
expression on platelets was signiﬁcantly higher than on HCAEC
and HCASMC (Fig. 3C, P < 0.01). Platelet csPDI expression was un-
changed by exposure to the trypsin reagent used to detach vascular
cells from culture ﬂasks (data not shown), indicating that our re-
sults were not due to differences in cell preparation prior to ﬂow
cytometric analysis. Consistent with this, thiol reductase activity
was signiﬁcantly greater on platelets than on HCAEC and HCASMC
(P < 0.01), when results were normalized for cell protein, with
platelets showing approximately sixfold and 15-fold higher activ-
ity than HCAEC and HCASMC, respectively (Fig. 4). To take into ac-
count the effect of differences in surface area between the cell
types, we measured the number of cells required to provide an
equal amount (1 lg) of protein as 68,000, 380 and 540 for platelets,
HCAEC and HCASMC, respectively. Estimates of platelet surface
area range from 14 lm2 [19] to 22 lm2 [20]. The diameter of tryp-
sinised HCAEC and HCASMC ranges from 10 to 25 lm (personal
communication, Promocell, Heidelberg), so taking a mean value
of 17.5 lm, and assuming a spherical shape for these cells, their
average surface area can be estimated as 962 lm2. Taking this va-
lue, and a mean platelet value of 18 lm2, it can be calculated thatFig. 1. 96-well microplate ﬂuorescence assay for thiol reductase activity. Di-E-GSSG (1
washed human platelets (0–16  107 per well) (B). Fluorescence was monitored over 120
(relative ﬂuorescence unit per min) was calculated. Samples were assayed in triplicate athe excess of platelet surface area in our experiments was 3.3-fold
compared with HCAEC and 2.4-fold compared with HCASMC. Thus
it appears that discrepancy in cell surface area does not fully ac-
count for the higher csPDI activity seen in platelets.
In experiments to determine the effect of cell activation on
csPDI activity, stimulation with PMA and ionomycin signiﬁcantly
increased the reductase activity on platelets and HCASMC
(P < 0.01), but no changes were detected on HCAEC (Fig. 5A and B).
GSNO mediated NO entry into platelets, HCAEC and HCASMC
Compared with both HCAEC and HCASMC, intracellular NOx
delivery from GSNO was greater in platelets (P < 0.001) (Fig. 6A).
Because of differences in absolute DAF-FM ﬂuorescence values be-
tween the different cell types, NOx delivery was normalized to the
percentage of maximal signal obtained following exposure to a
GSNO concentration of 1 mM. The results showed a greater propor-
tional increase in platelets than in the other cell types, indicating
that platelets are better able than HCAEC and HCASMC to receive
NOx at low concentrations of GSNO. When thiol isomerases were
blocked using PAO, the percentage inhibition of DAF-FM ﬂuores-
cence following GSNO exposure was higher for platelets than for
endothelial cells or smooth muscle cells (P < 0.05) (Fig. 6B), indicat-
ing that platelets rely more heavily on thiol isomerases for NOx
delivery.
Discussion
We have established techniques to measure the expression and
reductase activity of surface thiol isomerases on different cell50 nM) was incubated with serially diluted bovine liver PDI (0–160 nM) (A) and
min with excitation at 510 nm and emission at 550 nm, and the initial rate of change
nd data represent mean ± SEM from three separate experiments.
Fig. 3. Expression of csPDI on HCAEC, HCASMC and human platelets. (A) Washed platelets and vascular cells were characterized by forward (FSC) and side scatter (SSC). The
gated cells (R1) were analyzed. (B) Surface staining of the cells with PE-labelled isotype-matched control antibody (IgG1) (red) and anti-PDI antibody (blue). (C) The anti-PDI
antibody positive cells were quantiﬁed. Percentage positivity in HCAEC and HCASMC was signiﬁcantly lower compared with platelets (⁄⁄P < 0.01). Data represent
means ± SEM from three separate experiments. Values are expressed as a percentage of positivity in 10,000 cells (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article).
Fig. 4. Comparison of thiol reductase activity on HCAEC, HCASMC and human
platelets. Vascular cells (105/ml) and platelets (108/ml) were incubated with
Di-E-GSSG (150 nM) and thiol reductase activity was measured by monitoring
change in ﬂuorescence (Ex 510 nm/Em 550 nm) for 30 min. Values are corrected for
amount of cell protein to take account of differences in cell size and number. As an
internal control, maximum available ﬂuorescence was measured in parallel by
incubating Di-E-GSSG with10 mM DTT for 30 min, and results were then expressed
as a percentage of this maximum value. Data represent mean ± SEM from three
separate experiments, each performed in triplicate. ⁄⁄P < 0.01.
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ever the Di-E GSSG assay and the PAO inhibitor used in our exper-
iments are non-speciﬁc, so the functional activity detected may
derive from other isomerases in addition to PDI. Flow cytometric
determination of csPDI showed the highest percentage positivity
on platelets, whereas both vascular smooth muscle and endothelial
cells displayed a wider spread of expression, with some cells show-ing high activity but the majority being negative. Functionally ac-
tive thiol isomerase was higher on platelets than on either of the
two vascular cell types, and this heightened activity on platelets
was not fully accounted for by increased availability of cell surface
area. In addition, platelets showed an increase in thiol isomerase-
dependent NO delivery.
The presence of csPDI has been documented on a variety of cell
types [21] however the processes governing localisation of PDI to
the cell surface are not fully determined. In hepatocytes PDI secre-
tion is mediated by microtubular activity and attachment to the
plasma membrane appears to involve electrostatic interactions. Se-
creted PDI continues to display the KDEL endoplasmic reticulum
(ER) retention signal and it is speculated that secretion may arise
via leakage from a salvage pathway whose function is to recycle
proteins to the ER [22].
Several groups have shown that PDI is present inside endothe-
lial cells and that it is up-regulated under conditions of hypoxia
[22–25], during which it becomes a target for S-nitrosylation
[26]. It is not yet clear whether PDI becomes upregulated on the
cell surface in hypoxia. Endothelial cells in culture also express
PDI on their exofacial surface in a punctuate distribution, possibly
reﬂecting a concentration at cellular projections [9,27]. This csPDI
regulates the adhesive properties of both thrombospondin [27] and
of its binding partner integrin avb3 [28], and in addition catalyses
transnitrosation of endothelial target molecules [29]. In contrast,
experiments performed using mouse models of thrombus forma-
tion indicate that, in vivo, csPDI is not expressed on the endothelial
surface of the unperturbed vessel wall, but that it accumulates rap-
idly following vascular injury [30,31]. The observed kinetics of
Fig. 5. Effects of cellular activation on thiol reductase activity on HCAEC, HCASMC and human platelets. Following addition of PMA (A) and ionomycin (B) (both 1–100 lM),
vascular cells (105/ml) and platelets (108/ml) were incubated with Di-E-GSSG (150 nM) for 30 min to measure change of ﬂuorescence (Ex 510 nm/Em 550 nm). Results are
expressed as percentage increase compared with untreated control, and data represent mean ± SEM from three separate experiments, each performed in triplicate. Both PMA
and ionomycin increased thiol reductase activity in HCASMC and platelets however no increase was observed in HCAEC. This difference was signiﬁcant (P < 0.01) when
analyzed by Two-way ANOVA followed by Bonferroni post hoc correction for multiple comparisons.
Fig. 6. Intracellular NO delivery from GSNO. (A) DAF-FM diacetate-loaded vascular cells (105/ml) and platelets (108/ml) were incubated with GSNO (107–104 M) at 37 C for
15 min, and entry of NO-related signalling was measured by increase in ﬂuorescence intensity (Ex 495 nm/Em 550 nm). To take account of differences in absolute
ﬂuorescence values between the different cell types, parallel measurements of maximum ﬂuorescence (deﬁned as response to 103 M GSNO) were made and responses
reported as percentage of this maximum value. Intracellular NO delivery was greater in platelets, compared with both HCAEC and HCASMC (P < 0.001), whereas there was no
signiﬁcant different between HCAEC and HCASMC. Data were analyzed by Two-way ANOVA followed by Bonferroni post hoc correction for multiple comparisons. (B) To
determine the thiol isomerase dependence of NO delivery in each cell type, ﬂuorescence changes in response to 1 mM GSNO were measured following pre-incubation with
PAO (100 uM) for 30 min. Values are expressed as percentage inhibition vs untreated controls. Data represent mean ± SEM from three separate experiments, each performed
in triplicate. (⁄P < 0.05, ⁄⁄P < 0.01 by One-way ANOVA followed by Bonferroni post hoc correction for multiple comparisons).
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rives from both disrupted vascular cells and also from platelets
adhering at the site of injury. csPDI has been detected on endothe-
lial cells by ﬂow cytometry [9] and in one study [28] the percent-
age of endothelial cells showing positivity for csPDI was much
higher than our observed results. This discrepancy may arise from
our use of primary cells in contrast to the EA.hy926 cell line (de-
rived from fusion of endothelial and lung carcinoma cells) used
in the earlier study.
PDI is present inside vascular smooth muscle cells and shows a
shift to the membrane fraction (detectable by both western blot-
ting and increased refolding activity) following cell stimulation
with angiotensin II. Under these conditions membrane-associated
PDI appears to co-localise with and regulate the activity of NADPH
oxidase [32]. In similar fashion, activation of platelets is associated
with increased secretion of both PDI [33] and a range of other thiol
isomerases which go on to modulate various aspects of platelet
function [34,35]. It should be noted, however, that csPDI is also
present on the surface of resting platelets [33,36], so activation is
not required for csPDI to be displayed. We found that cell activa-
tion with PMA and ionomycin brought about an increase in thiolreductase activity on both platelets and smooth muscle cells, how-
ever this effect was not apparent in endothelial cells. PMA and ion-
omycin were deliberately chosen in order to stimulate generic
intracellular signaling pathways (involving protein kinase C and
intracellular calcium, respectively), so the variation in response be-
tween the cell types was not due to differential expression of par-
ticular agonist receptors. Interestingly, in hepatocytes the
extracellular secretion of PDI was actually reduced by cellular
stress in the form of tunicamycin treatment or heat shock [22],
so it is clear that the effects on surface thiol isomerases of cell
stress/stimulation are not uniform across cell types.
Our measurements of cell surface thiol reductase activity were
made using a 96-well plate adaptation of the original method de-
scribed by Raturi and Mutus [18] which allowed the use of small
sample volumes. Our results clearly showed that platelets possess
a more active surface, in this respect, than endothelial and smooth
muscle cells. In parallel, the delivery of NOx into platelets was
greater than into the other cell types, and the degree of thiol isom-
erase-dependence was greatest for platelets, as reﬂected in the loss
of NO delivery brought about by the thiol isomerase inhibitor PAO.
The degree of PAO-mediated inhibition of NO uptake was smaller
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high concentrations of GSNO, denitrosation by thiol isomerases is
not the sole mechanism of NO delivery. In these experiments,
DAF-FM was used to detect the arrival of NO-related signalling in-
side cells. This ﬂuorescent probe measures a range of NO/oxygen
reaction products, therefore it is not possible to specify the identity
of the NO derivative which is delivered. The NO donor used for
these experiments was GSNO, so these results are relevant to the
previously described clinical data indicating platelet-selective
action of this agent [16].
Research into the mechanisms by which cells take up NO from
impermeable donor compounds such as GSNO has highlighted
two major pathways: NO release in the proximity of the plasma
membrane by denitrosating enzymes (such as csPDI) (10–12), and
transnitrosation to cysteine followed by import of intact S-nitroso-
cysteine via the L-AT family of amino aid transporters [37].We have
previously argued that the former mechanism is more important in
platelets [15] and the results of the present study are consistent
with this hypothesis. We suggest that the platelet selective actions
of GSNO result from platelet surface thiol isomerases metabolising
GSNO more rapidly than the endothelial lining of the blood vessel
wall, allowing anti-platelet action of NO to occurwithout signiﬁcant
NO delivery to vascular smooth muscle to bring about vasodilation.
The emerging evidence of PDI involvement in various components
of haemostasis/thrombosis suggests that differential csPDI avail-
ability may have wider relevance for vascular biology which goes
beyond nitric oxide delivery alone.
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